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Introduction 
In accordance with Article 5 of the Council Decision 2005/387/JHA on the information exchange, risk-
assessment and control of new psychoactive substances (1) on 25 April 2017, the EMCDDA and 
Europol launched the Joint Report procedure for N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]oxolane-
2-carboxamide (tetrahydrofuranylfentanyl) on the basis of data reported by the Member States to the 
European Union Early Warning System in accordance with Article 4 of the Council Decision. The 
information collection process for the Joint Report was completed in June 2017. The report was 
submitted to the EU Institutions in July 2017 (EMCDDA, 2017a). In accordance with Article 6 of the 
Council Decision, on 14 September 2017, the Council of the European Union requested that a risk 
assessment on tetrahydrofuranylfentanyl should be carried out by the extended Scientific Committee 
of the EMCDDA. 
In order to prepare for the risk assessment, and, to facilitate the risk assessment process, the 
EMCDDA is responsible for the collection and analysis of data on the substance to be assessed as 
well as drafting a technical report. This technical report has been prepared for the risk assessment of 
tetrahydrofuranylfentanyl that will be held at the EMCDDA premises in Lisbon on Wednesday 8 
November 2017. 
Some of the sections in this report were prepared under EMCDDA contracts (ref. CT.17.SAT.0084.1.0 
and CT.17.SAT.0110.1.0). 
Data sources 
The information in this technical report is derived from: 
 data reported by the Member States, Turkey, and Norway to the EMCDDA and Europol in 
accordance with Council Decision 2005/387/JHA (EMCDDA, 2017a); and,  
 data collected through systematic searches of open source information, including the 
scientific and medical literature, patents, official reports, grey literature, online drug discussion 
forums and related websites, and online vendors selling tetrahydrofuranylfentanyl. 
Search strategy  
Literature searches used both chemical structure and text queries in online databases; searches were 
conducted in August 2017. The retrieved publications were then scanned for additional relevant 
references (snowballing technique). 
Chemical structure-based searches were done in SciFinder® (American Chemical Society, Chemical 
Abstract Service) and Reaxys® (Elsevier) databases using both the exact structure and substructure 
of tetrahydrofuranylfentanyl as well as a similarity search. Structural and text-based searches in 
SureChEMBL patent database retrieved no hits. 
Textual searches were conducted online in PubMed (National Center for Biotechnology Information), 
Web of  (Thomson Reuters), and in popular English-language online drug forums. The 
                                                     
(1) OJ L 127, 20.5.2005, p. 32.  
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search terms used were: tetrahydrofuranylfentanyl  tetrahydrofuranyl-  tetrahydrofuranyl 
 THF-   tetrahydrofuranyl   
The REACH registered substances database hosted by the European Chemicals Agency (ECHA) 
was searched using the CAS registry numbers listed above. The searches returned no hits. 
Cursory, though repeated, inspections of English-language Internet forums covered Bluelight, Drugs-
forum, ecstasydata.org, Erowid, Eve&Rave, Reddit and The Vespiary. 
Additionally, the scientific networks of the authors were contacted to obtain information. 
Note 
It is important to note that when interpreting the information on self-reported user experiences in this 
report, it is not possible to confirm the specific substance(s) that have been claimed to be used; 
similarly it is also not possible to confirm the strength, purity, dose/amount, etc., used. Moreover, the 
actual composition of the substance/product may differ over time and different geographical areas. In 
addition, the information provided on user websites may not necessarily be representative of other 
users of tetrahydrofuranylfentanyl and should be regarded as illustrative only. In general, given the 
difficulties of collecting accurate self-reported data, it should be interpreted with caution. 
Reported prepared by 
Simon Brandt (2), Simon Elliott (3), Michael Evans-Brown (4), Helgi Valur Danielsson (4), Anabela 
Almeida (4), Rita Jorge (4), Rachel Christie (4), Sofía Sola (4), Ana Gallegos (4), and Roumen Sedefov 
(4). 
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Ujváry, iKem BT, Budapest, Hungary for reviewing some of the sections of this report.  
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Section A. Physical, chemical, pharmaceutical and pharmacological information 
A1. Physical, chemical, and pharmaceutical information 
A1.1. Physical and chemical description 
Chemical description and names 
N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]oxolane-2-carboxamide (tetrahydrofuranylfentanyl) is a 
tetrahydrofuran-2-carboxamide derivative of N-phenyl-1-(2-phenylethyl)piperidin-4-amine (4-ANPP) 
and structurally related to fentanyl, which is a propionamide (Table 1). Tetrahydrofuranylfentanyl 
contains one basic nitrogen atom in the piperidine ring and readily forms salts with organic or 
inorganic acids. 
Tetrahydrofuranylfentanyl has one positional isomer, which is 3-tetrahydrofuranylfentanyl. In 3-
tetrahydrofuranylfentanyl, the carboxamide is attached to the 3-position of the tetrahydrofuran ring 
(5).Tetrahydrofuranylfentanyl contains a stereogenic centre thus allowing for the existence of a pair of 
enantiomers, (S)-tetrahydrofuranylfentanyl and (R)-tetrahydrofuranylfentanyl. There is no information 
on the actual enantiomer found on the European drug market or whether it is the racemic mixture. 
Until recently (Helander et al., 2017), information about tetrahydrofuranylfentanyl could not be 
identified in the scientific literature, which suggests that this compound appears to have no published 
history. 
Tetrahydrofuranylfentanyl is a close structural relative of fentanyl (6,7), which is a fast and short-acting 
synthetic opioid that has been widely used in clinical practice as an adjunct to general anaesthesia 
during surgery and for pain management.  
Tetrahydrofuranylfentanyl is the saturated derivative of furanylfentanyl (8) which was the subject of an 
EMCDDA Europol Joint Report in January 2017 and risk-assessed under the auspices of the 
Scientific Committee of the EMCDDA in May 2017 (EMCDDA, 2017b). Tetrahydrofuranylfentanyl is 
also structurally related to acetylfentanyl and acryloylfentanyl, both of which were the subject of 
EMCDDA Europol Joint Reports in December 2015 and November 2016, following reports of deaths 
in Europe. In February 2017, the risk assessment meeting on acryloylfentanyl (EMCDDA, 2017c) was 
convened. On 25 September 2017, the Council of the European Union decided that acryloylfentanyl 
should be subjected to control measures across the European Union (Council of the European Union, 
2017). 
 
                                                     
(5) Throughout this report,  refers to 2-tetrahydrofuranylfentanyl. 
(6) http://www.emcdda.europe.eu/publications/drug-profiles/fentanyl  
(7) Fentanyl is included in Schedule I of the United Nations Single Convention on Narcotic Drugs, 1961, as amended by the 
1972 Protocol. 
(8) Tetrahydrofuranylfentanyl contains a tetrahydrofuran (aliphatic ring), whereas furanylfentanyl contains a furan (aromatic 
derivative of tetrahydrofuran). Furanylfentanyl might be used as a precursor for the synthesis of tetrahydrofuranylfentanyl; 
however, this has not been documented.  
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Fifteen fentanils are controlled under the United Nations Single Convention on Narcotic Drugs, 1961, 
as amended by the 1972 Protocol: 3-methylfentanyl, 3-methylthiofentanyl, acetyl-alpha-
methylfentanyl, acetylfentanyl, alpha-methylfentanyl, alpha-methylthiofentanyl, beta-hydroxy-3-
methylfentanyl, beta-hydroxyfentanyl, para-fluorofentanyl and thiofentanyl, are controlled under 
Schedule I and IV; alfentanil, butyrfentanyl, fentanyl, remifentanil and sufentanil are controlled under 
Schedule I. The controls on acetylfentanyl and butyrfentanyl entered into force in 2016 and 2017, 
respectively. 
Names and other identifiers 
Systematic International Union of Pure and Applied Chemistry (IUPAC) name: 
N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]oxolane-2-carboxamide 
Chemical Abstract name:  
2-Furancarboxamide, tetrahydro-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]- 
Other names:  
N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran-2-carboxamide 
N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide 
Tetrahydrofuranylfentanyl Furanylfentanyl Fentanyl 
    
C24H30N2O2 C24H26N2O2 C22H28N2O 
378.52 g/mol 374.48 g/mol 336.48 g/mol 
Figure 1: The molecular structure, molecular formula and molecular mass of tetrahydrofuranylfentanyl (left), 
furanylfentanyl (middle) and fentanyl (right). The asterisk denotes a chiral carbon. 
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Chemical Abstract Service Registry Numbers (CAS RNs) (9):  
Not registered  
PubChem SID (10):  
Not registered  
IUPAC International Chemical Identifier Key (InCHI Key) (11):  
OHJNHKUFSKAANI-UHFFFAOYSA-N 
SMILES (12):  
O=C(C1=CC=CO1)N(C2=CC=CC=C2)C3CCN(CCC4=CC=CC=C4)CC3 
Common names:  
Tetrahydrofuranylfentanyl; tetrahydrofuranfentanyl; tetrahydrofuran fentanyl; tetrahydrofuranyl 
fentanyl; tetrahydrofuran-fentanyl; THF-F 
Street names:  
THF-fentanyl; tetrahydrofuran-F; Tetra. 
Identification and analytical profile 
Physical description  
Tetrahydrofuranylfentanyl hydrochloride has been described as a crystalline solid (Cayman Chemical 
Company, 2017) and the free base as a white powder (SWGDRUG, 2017). Tetrahydrofuranylfentanyl 
hydrochloride has been reported to be soluble in dichloromethane, methanol and water (Slovenian 
National Forensic Laboratory, 2017). Due to its similarity to fentanyl, the free base could be expected 
to be sparingly soluble in water; the hydrochloride and citrate salt could be expected to have greater 
aqueous solubility. Tetrahydrofuranylfentanyl, similar to fentanyl, is expected to be lipophilic (13). 
Tetrahydrofuranylfentanyl has been seized as a liquid and in powder form. A more detailed 
description of seizures and collected samples can be found in Section C. 
                                                     
(9) The Chemical Abstract Service Registry Number (CAS RN) is a unique numeric identifier assigned by the Chemical Abstract 
Service Division of the American Chemical Society to a specific, single chemical substance. Search conducted on 23 October 
2017. 
(10) Search conducted on 23 October 2017 at https://pubchem.ncbi.nlm.nih.gov. 
(11) InChI Key is a unique, non-proprietary structural identifier of chemical substances useful in electronic sources. 
(12) The simplified molecular-input line-entry system (SMILES) is a unique, non-proprietary structural identifier of chemical 
substances useful in electronic sources. 
(13) The respective calculated LogP values for tetrahydrofuranylfentanyl and fentanyl are 3.04 and 3.89 (ACD/ChemSketch 
2015 release version, Advanced Chemistry Development Inc., Toronto, Canada). The respective LogP values calculated by 
StarDrop version 6.3.1 software (Optibrium Ltd, Cambridge, UK) for acryloylfentanyl and fentanyl are 4.18 and 3.89. The 
measured LogP value for fentanyl is 4.05 (Hansch et al., 1995). 
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Chemical stability and typical reactions 
Specific information about tetrahydrofuranylfentanyl could not be identified. For long-term storage it is 
recommended that tetrahydrofuranylfentanyl, supplied as a solid, is stored at -20 °C (Cayman 
Chemical Company, 2017).  
Analytical profile 
Analytical data for tetrahydrofuranylfentanyl include: gas chromatography mass spectrometry (GC-
MS), high performance liquid chromatography (high resolution) (tandem) mass spectrometry (LC-
HRMS), Fourier transform infrared spectroscopy attenuated total reflectance (FTIR-ATR), proton 
nuclear magnetic resonance (1H NMR) spectroscopy and gas chromatography condensed phase 
infrared spectroscopy and ion chromatography (GC- (MS)-IR) (Helander et al., 2017; Slovenian 
National Forensic Laboratory, 2017; SWGDRUG, 2017). Studies on the ability to differentiate between 
the 2- and 3-tetrahydrofuranylfentanyl isomers or enantiomers could not be identified (14). 
It is possible that immunoassays for fentanyl may not detect or distinguish between 
tetrahydrofuranylfentanyl and fentanyl due to the structural similarity between the two substances (US 
DEA, 2016a). Identification of tetrahydrofuranylfentanyl therefore would require further confirmatory 
analysis using more suitable detection techniques, such as (tandem) mass spectrometry (Helander et 
al., 2017). Similarly, tetrahydrofuranylfentanyl is not expected to give a positive response to tests 
developed for morphine-type opioids. 
Recently, a new bioassay-based method which relies on the activation of the -opioid receptor 
signalling pathway for the detection of synthetic opioids, including tetrahydrofuranylfentanyl, has been 
reported (Cannaert et al., 2017). 
Methods and chemical precursors used for the manufacture 
No information was reported to the EMCDDA about the chemical precursors or manufacturing 
methods used to make the tetrahydrofuranylfentanyl that has been detected on the drug market in 
Europe. However, analysis of a collected sample of tetrahydrofuranylfentanyl that was test purchased 
from an online vendor apparently based in China also identified -aminophenyl-1-
 i.e. N-phenyl-1-(2-phenylethyl)piperidin-4-amine (4-ANPP) (Slovenian National 
Forensic Laboratory, 2017), which is a commonly used precursor for synthesising many fentanyl 
analogues.  
Detailed or quantitative information available with regards to route-specific by-products produced 
during the synthesis of tetrahydrofuranylfentanyl is not available. 
Synthesis 
A synthesis procedure for tetrahydrofuranylfentanyl could not be identified in the literature. It is likely 
that its synthesis relies on precursors and synthetic methods similar to those used for the 
manufacture of pharmaceutical fentanyl and other fentanyl analogues. Accordingly, methods 
developed for the multistep synthesis of fentanyl are applicable to tetrahydrofuranylfentanyl but use a 
                                                     
(14) 3-Tetrahydrofuranylfentanyl is also commercially available as a reference standard: 
https://www.caymanchem.com/product/22664  
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different acylating agent in the acylation of the appropriate 4-phenylaminopiperidine precursor. For 
example, the synthesis method of tetrahydrofuranylfentanyl could use the acylation of the N-phenyl-1-
(2-phenylethyl)piperidin-4-amine (4-ANPP) intermediate, a precursor common to fentanyl and other 
fentanyl analogues, with tetrahydrofuran-2-carbonyl chloride (Figure 2). As mentioned above, the 
detection of the 4-ANPP precursor was reported as part of the analysis of a test purchase product. 
The preparation of the 3-tetrahydrofuranylfentanyl isomer would be expected to involve the use of 
tetrahydrofuran-3-carbonyl chloride as the acylating agent. It has been demonstrated that N-(2-
furoyl)piperazine could be directly reduced to N-(tetrahydro-2-furoyl)piperazine (Gluchowski et al., 
2000) but whether this is applicable to the reduction of furanylfentanyl to tetrahydrofuranylfentanyl 
remains to be studied. If this were feasible then it would suggest that furanylfentanyl might serve as a 
precursor to tetrahydrofuranylfentanyl.  
Most of these synthetic procedures are relatively straightforward. Due to the typical high potency of 
fentanils there is a risk of severe poisoning following accidental exposure during their manufacture. 
Extreme care must be taken when carrying out the final synthetic step as well as when purifying and 
handling the substances. Likewise, accidental exposure to the fentanils could pose a risk of poisoning 
to the public, law enforcement, emergency personnel, as well as medical and forensic laboratory 
personnel. In addition to exercising extreme caution when handling materials suspected to contain 
fentanils, personnel should be equipped with appropriate protective equipment. The antidote naloxone 
should be readily available to personnel in sufficient quantities; training in resuscitation, including the 
administration of naloxone, should also be available (IAB, 2017; US CDC, 2013; US CDC, 2016; US 
DEA, 2017b).  
The 4-ANPP precursor, as well as N-phenethyl-4-piperidone (NPP, a pre-precursor), were scheduled 
in 2017 and are listed in Table I of the United Nations Convention against Traffic in Narcotic Drugs 
and Psychotropic Substances, 1988 (CND, 2017). The scheduling came into force on 18 October 
2017 (INCB, 2017). In 2010, the U.S. Drug Enforcement Administration placed 4-ANPP (named 
ANPP in the regulation) into Schedule II of the Controlled Substances Act in 2010 following its use as 
a precursor to make fentanyl in illicit laboratories (US DEA, 2010). Other routes developed for the 
production of fentanyl may also be used for the manufacture of tetrahydrofuranylfentanyl. These 
methods have been reviewed (Soine, 1986; Carroll and Brine, 1989; Hsu and Banks, 1992; Fritschi 
and Klein, 1995; Yadav et al., 2010; Vardanyan and Hruby, 2014). To date, there is no information on 
the actual method(s) used for the production of tetrahydrofuranylfentanyl that has been detected on 
the European drug market. 
Typical impurities encountered in seized and collected samples 
There are no quantitative data available on the impurities detected in seized and collected samples 
reported to the EMCDDA. A collected sample of tetrahydrofuranylfentanyl was reported to contain 4-
ANPP (Slovenian National Forensic Laboratory, 2017), which, as mentioned above, is a commonly 
used precursor for synthesising many fentanils.  
 
Figure 2. A possible step of the synthesis of tetrahydrofuranylfentanyl.  
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A1.2. Physical/pharmaceutical form  
Data from seizures and collected samples reported to the EMCDDA have noted that 
tetrahydrofuranylfentanyl has typically been detected in powders and liquids. 
A1.3. Route of administration and dosage  
As with other fentanils, tetrahydrofuranylfentanyl can be administered orally as a powder (including in 
capsules), as tablets, or as a solution (using nasal sprays) or by insufflation of a powder; it can also 
be administered intranasally or sublingually via a spray; inhaled by smoking or vaporizing; and, 
administered by injection (intravenous and intramuscular). Of note is that ready-to-use nasal sprays 
purportedly containing solutions of tetrahydrofuranylfentanyl have been offered by online vendors in 
Sweden. However, it is worth noting that some of these products are not always labelled and/or they 
may be sold as another substance. This finding extends to the use of other fentanils that have 
appeared in Europe in the past few years, including acryloylfentanyl (EMCDDA, 2017c; Ujváry et al., 
2017) and furanylfentanyl (EMCDDA, 2017b). 
Data reported to the EMCDDA regarding an acute intoxication with confirmed exposure to 
tetrahydrofuranylfentanyl noted that the substance was administered intra-nasally by nasal spray 
(Section D1.2). 
Dosage 
Limited information is available regarding the dose and the dose regimens of 
tetrahydrofuranylfentanyl. It is not possible to currently discern the  dosages administered by 
users. Doses appear to differ depending on factors such as the route of administration, the tolerance 
of the users, the use of other drugs, and the desired effects. Given the difficulties of collecting such 
data, it should be used with caution. Furthermore, the purity, amount and/or composition of the 
substance ingested are not typically known by the user. Moreover, the actual composition of the 
substance may differ over time and different geographical areas.  
One comment made on a user forum suggested that, upon insufflation, tetrahydrofuranylfentanyl was 
 at 2 mg  and that up to over 10 mg seems comfortable  in a user who also used kratom (15) 
several times a  (16). 
A2. Pharmacology, including pharmacodynamics and pharmacokinetics  
Pharmacologically, tetrahydrofuranylfentanyl is an opioid receptor agonist. 
  
                                                     
(15) Kratom refers to the M. speciosa plant known to contain constituents (e.g. mitragynine) with opioid-like activity (Raffa, 
2015).  
(16) https://drugs-forum.com/threads/tetrahydrofuranylfentanyl-info.295272/ (last accessed 07 September 2017). 
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Pharmacodynamics 
In vitro studies 
The currently available data suggests that tetrahydrofuranylfentanyl (17) binds to the -opioid receptor 
(MOR) with high selectivity (Ki = 0.95 nM) over the - and -opioid receptors (KOR and DOR) with Ki 
values of 741 nM and 1,730 nM, respectively (Table 1) (18) (US DEA, 2017a).  
Table 1 provides a summary of additional binding and functional activity data that illustrate that 
tetrahydrofuranylfentanyl (EC50 = 89 nM, [35  binding assay, Emax = 73.8%) functioned as a 
MOR agonist (19). In comparison, morphine (EC50 = 22.2 nM, [35  binding assay, Emax = 
81.0%) and fentanyl (EC50 = 15.2 nM, Emax = 90.4%) were approximately 4- and 6-times more potent 
than tetrahydrofuranylfentanyl and all three test drugs exhibited comparable efficacy under these in 
vitro conditions. 
                                                     
(17) Isomeric composition not specified. 
(18) Ki represents the equilibrium inhibition constant for the test drug displacing the radioligand. 
(19) EC50 represents the concentration that causes a half-maximal response of the agonist.  
Table 1. Opioid receptor binding and functional activity data of tetrahydrofuranylfentanyl (THF-F)* (adapted 
and modified from US DEA, 2017a). 
MOR THF-F  DAMGO Morphine Fentanyl Naltrexone 
[3H]DAMGO binding Ki (nM) 0.95 ± 0.32 0.252 ± 
0.052 
0.223 ± 
0.051 
0.056 ± 
0.010 
0.092 ± 0.017 
IC50 (nM) 4.4 ± 1.5     
[35S  binding THF-F  DAMGO Morphine Fentanyl  
Stimulation EC50 (nM) 89 ± 16 15.2 ± 3.3 22.2 ± 2.8 15.2 ± 2.1  
Maximal stimulation (%)* 73.8 ± 5.0 98.0 ± 4.1 81.0 ± 1.8 90.4 ± 2.2  
DOR THF-F  DPDPE-OH Morphine Fentanyl Naltrexone 
[3H]DPDPE binding Ki (nM) 1,730 ± 260 2.77 ± 0.50 186 ± 13 249 ± 57 17.4 ± 4.8 
IC50 (nM) 2,200 ± 300     
[35S  binding THF-F  DPDPE-OH Morphine Fentanyl  
Stimulation EC50 (nM) 1,440 ± 550 8.8 ± 2.1 566 ± 56 850 ± 140  
Maximal stimulation (%)** 16.2 ± 3.7 99.53 ± 0.34 79.6 ± 5.5 62.1 ± 30  
KOR THF-F  U-50,488H Morphine Fentanyl Nor-BNI 
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Tetrahydrofuranylfentanyl showed moderate affinity toward KOR (Ki = 741 nM) with low potency and 
moderate relative efficacy (EC50 = 5,790 nM, [35  binding assay, Emax = 62.1%). As far as 
DOR was concerned, binding affinity, potency and efficacy were relatively low (Ki = 1,730 nM, EC50 = 
1,440 nM, [35  binding assay, Emax = 16.2%), which suggested a MOR selective profile, at 
least under these in vitro conditions. All test drugs used as positive control (Table 1) were shown to 
be efficacious agonists.  
These in vitro studies have established tetrahydrofuranylfentanyl to be a MOR agonist. It is not 
known, however, to what extent this MOR agonist effect, which is responsible for causing respiratory 
depression (among other effects), would translate to high toxicity in vivo. 
These data also indicated that saturation of the furanyl ring (also found in furanylfentanyl, subject of a 
recent risk assessment in May 2017 (EMCDDA, 2017b) led to a significant drop in potency, when 
investigated under identical in vitro conditions. For example, tetrahydrofuranylfentanyl displayed a 34-
fold reduction in affinity (furanylfentanyl Ki = 0.0249 nM) and 35-fold drop in potency at MOR 
(furanylfentanyl EC50 = 2.52 nM, [35  binding) although furanylfentanyl was found to be 
somewhat more efficacious relative to the MOR agonist DAMGO (20) (furanylfentanyl Emax = 55.5% vs. 
Emax = 73.8%, Table 1, see above) (EMCDDA, 2017b; US DEA, 2016b). 
  
                                                     
(20) DAMGO: Tyr-Ala-Gly-N-Me-Phe-Gly-ol.  
[3H]U-69,593 binding Ki 
(nM) 
741 ± 44 0.274 ± 
0.063 
30.2 ± 1.4 121 ± 11 0.38 ± 0.10 
IC50 (nM) 1,720 ± 270     
[35S  binding THF-F  U-50,488H Morphine Fentanyl  
Stimulation EC50 (nM) 5,790 ± 430 1.62 ± 0.32 65 ± 19 700 ± 110  
Maximal stimulation (%)** 62.1 ± 5.3 96.5 ± 7.7 73.2 ± 5.9 60.8 ± 8.5  
* In receptor binding experiments, transfected Chinese hamster ovary (CHO) cells expressing human - and 
-opioid receptors and rat -opioid receptors were used. Experimental details for functional activity studies are 
not reported. DOR: delta opioid receptor; KOR: kappa opioid receptor; MOR: mu opioid receptor; DAMGO: 
Tyr-Ala-Gly-N-Me-Phe-Gly-ol, DPDPE: Tyr-Pen-Gly-Phe-Pen [disulfide bridge: 2-5]; U-69,593: (+)- -
N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide; U-50,488H: trans-(±)-3,4-dichloro-
N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide methanesulfonate salt; Nor-BNI: 
norbinaltorphimine; U-69,593: (+)- -N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-
benzeneacetamide. SEM: standard error of the mean.  
Numbers represent the means ± SEM from at least three independent experiments, each conducted with 
duplicate determinations. Standard compounds are the agonists DPDPE (delta), U50,488H (kappa) and 
DAMGO (mu) and the antagonists naltrexone (delta and mu) and nor-BNI (kappa). 
** Maximal stimulation by test compound is normalized to the maximal stimulation by DPDPE (delta), 
U50,488H (kappa) or DAMGO (mu) above basal. Negative values indicate inhibition of basal [35S  
binding. 
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Animal studies 
Results from animal studies could not be identified. 
Pharmacokinetics 
Apart from a recent conference abstract briefly discussing in vitro experiments with a series of 
fentanyl analogues, no in vitro or in vivo studies could be identified in the literature. According to this 
report (Wilde et al., 2017), in a human liver microsomal preparation the predominant metabolic step 
for tetrahydrofuranylfentanyl appears to be N-desalkylation, as in the case of fentanyl. Hydroxylation 
of the piperidine ring and the phenylethyl side chain, N-oxidation and amide hydrolysis to 4-ANPP 
were also observed. 
The extent to which the biotransformation products are comparable to furanylfentanyl or other closely 
related analogues remains to be investigated. It seems likely that some overlap might exist, including 
the amide hydrolysis product 4-ANPP (Watanabe et al., 2017).  
There is some information on the biological activity of 4-ANPP using intact guinea pig ileum 
preparations. Compared to fentanyl (IC50 = 4 nM), 4-ANPP was significantly less potent in inhibiting 
contractions of ileum segments induced by coaxial electrical stimulation (IC50 = 12,000 nM). The IC50 
value determined for morphine was 50 nM (Schneider and Brune, 1986). Two metabolites showed 
activity in this study: the phenolic derivative hydroxylated at the 4-position of the phenylethyl moiety of 
fentanyl (21), the activity (IC50 = 240 nM) of which was found to lie between morphine and pethidine 
(IC50 = 1,300 nM), and the benzylic alcohol type derivative hydroxylated at the alpha-position, i.e. 
benzylic methylene, of the phenylethyl moiety of fentanyl which had an IC50 value of 50 nM.  
One user described the high  obtained from insufflating an estimated  of 20 mg of 
tetrahydrofuranylfentanyl to last for about 2 hours (route of administration ( insufflation ) (22).  
Inter-individual genetic variability in metabolising enzymes 
Specific information about tetrahydrofuranylfentanyl could not be identified. For fentanyl, oxidative 
dealkylation by hepatic CYP3A4 and by CYP3A5 isoenzymes to norfentanyl has been demonstrated 
(Guitton et al., 1997, Jin et al., 2005, Labroo et al., 1997) The variation of the expression of the genes 
coding for these CYP3A isoenzymes among populations might be of clinical significance (Meyer and 
Maurer, 2011) but further studies are needed to examine the toxicological significance, if any, of such 
polymorphisms.  
Interactions with other substances and other interactions 
Specific information about tetrahydrofuranylfentanyl could not be identified, although it seems 
conceivable that interactions observed with fentanyl might equally apply (Preston, 2016). For 
example, should tetrahydrofuranylfentanyl undergo oxidative dealkylation by hepatic CYP3A4 and by 
CYP3A5 isoenzymes then the use of this substance with inhibitors of these isoenzymes, such as 
clarithromycin, erythromycin, fluconazole, grapefruit juice, indinavir, itraconazole, ketoconazole, 
                                                     
(21) Systematic name: N-{1-[2-(4-hydroxyphenyl)ethyl]piperidin-4-yl}-N-phenylpropionamide. 
(22) https://drugs-forum.com/threads/tetrahydrofuranylfentanyl-info.295272/ (last accessed 07 September 2017).   
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nefazodone, ritonavir, saquinavir, suboxone, verapamil (23) may result in increased plasma 
concentration of tetrahydrofuranylfentanyl. This could increase the risk of poisoning, including 
potentially fatal respiratory depression.  
The concomitant use of other central nervous system (CNS) depressants with 
tetrahydrofuranylfentanyl, such as other opioids, sedatives/hypnotics (such as the benzodiazepines 
and the z-drugs), ethanol, pregabalin, gabapentin, tranquillisers, and sedating anti-histamines, may 
produce additive depressant effects.  
The use of fentanyl with serotoninergic agents, such as selective serotonin re-uptake Inhibitors 
(SSRIs) (the most commonly prescribed antidepressants) or serotonin norepinephrine re-uptake 
inhibitors (SNRIs) or monoamine oxidase inhibitors (MAOIs) has been associated with a serotonin 
syndrome, a potentially life-threatening condition. This association is likely to extend to illicit drugs, 
which act on the serotonergic system. It is not known if this association is also seen with 
tetrahydrofuranylfentanyl.  
Effects on ability to drive and operate machines 
No studies of the effects of tetrahydrofuranylfentanyl on the ability to drive and operate machines 
have been performed. However, it is well established that opioid analgesics, such as fentanyl, impair 
the mental and physical ability required to drive and operate machines. This effect is likely to extend 
to tetrahydrofuranylfentanyl. 
A3. Psychological and behavioural effects 
Information on the psychological and behavioural effects of tetrahydrofuranylfentanyl is limited. From 
the data available, it appears that the psychoactive profile of tetrahydrofuranylfentanyl might share at 
least some similarities with other opioid analgesics such as fentanyl and heroin (24).These would 
include relaxation and euphoria; at higher doses, sedation and profound intoxication may occur. 
A4. Legitimate uses of the product  
Tetrahydrofuranylfentanyl is used as an analytical reference material in clinical and forensic case 
work/investigations as well as scientific research. There is currently no information that suggests 
tetrahydrofuranylfentanyl is used for other legitimate purposes. 
There are no reported uses of tetrahydrofuranylfentanyl as a component in industrial, cosmetic or 
agricultural products. In addition, a search of the Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) registered substances database hosted by the European 
Chemicals Agency (ECHA) using the CAS Registry Number for tetrahydrofuranylfentanyl returned no 
results. 
                                                     
(23) For a more comprehensive list of drug interactions with fentanyl, see, for example, 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124&source
=homeMedSearch&keyword=fentanyl&category=human&isNewQuery=true 
(24) One user described a  rush, high lasts about 2 hours, very clean and warm. Taking maybe (eyeballed) 20 mg within 2 
hours caused intense  https://drugs-forum.com/threads/tetrahydrofuranylfentanyl-info.295272/ (last accessed 07 
September 2017).   
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There is no marketing authorisation (existing, on-going or suspended) for tetrahydrofuranylfentanyl 
neither in the European Union nor in the Member States that responded to the request for information 
from the European Medicines Agency, which was undertaken as part of the Joint Report process 
(EMCDDA, 2017a). 
There is no information to suggest that tetrahydrofuranylfentanyl is currently used in the manufacture 
of a medicinal product in the European Union. However, in the absence of a database on the 
synthetic routes of all medicinal products it is not possible to confirm whether or not 
tetrahydrofuranylfentanyl is currently used in the manufacture of a medicinal product.  
Section B. Dependence and abuse potential 
B1. Animal data  
No studies were identified that have investigated the dependence and/or abuse potential of 
tetrahydrofuranylfentanyl in animal models.  
B2. Human data  
No studies were identified that have investigated the dependence and/or abuse potential of 
tetrahydrofuranylfentanyl in humans.  
While no specific data exist for tetrahydrofuranylfentanyl, it is well established that opioid analgesics 
such as fentanyl have an abuse liability and can induce tolerance and dependence. Research is 
required in order to examine these effects with tetrahydrofuranylfentanyl. 
Section C. Prevalence of use 
Information from seizures, collected and biological samples 
Tetrahydrofuranylfentanyl was formally notified on 23 December 2016 by the EMCDDA on behalf of 
Sweden, in accordance with Article 4 of the Council Decision. The Reporting Form details a seizure of 
22 millilitres of pale yellow liquid that was seized on 29 September 2016 by Swedish Police in 
Karlstad. The substance was analytically confirmed by GC-MS, liquid chromatography high resolution 
mass spectrometry (LC HRMS) and NMR by the Swedish National Forensic Centre.  
Two Member States (Slovenia and Sweden) have reported detections of tetrahydrofuranylfentanyl (25) 
(EMCDDA, 2017a).  
It is important to note that detections of tetrahydrofuranylfentanyl may be under-reported since the 
substance is not routinely screened for in Europe. Three Member States (Austria, Slovenia and 
                                                     
(25)  is an all-encompassing term and may include seizures and/or collected and/or biological samples that are 
analytically confirmed. Seizure means a substance available (seized) through law enforcement activities (police, customs, 
border guards, etc.). Collected samples are those that are actively collected by drug monitoring systems (such as test 
purchases) for monitoring and research purposes. Biological samples are those from human body fluids (urine, blood, etc.) 
and/or specimens (tissues, hair, etc.).  
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Sweden) reported that tetrahydrofuranylfentanyl is part of routine screening in some, but not all, 
laboratories. 
Information from seizures 
In total, 53 seizures of tetrahydrofuranylfentanyl were reported to the EMCDDA and Europol. All of 
these were reported by Sweden. Of these, 26 seizures occurred in 2016, and the other 27 in the first 
6 months of 2017.  
A majority of the seizures were made by police at street-level (50 cases), with the remaining three 
seizures made by customs. 
Physical forms seized included:  
 liquids (48 seizures; amounting to a total volume of 950 millilitres of substance)  
 powders (5 seizures; 99.4 grams) 
No quantitative information on purity was reported. In all the cases, tetrahydrofuranylfentanyl was the 
only substance reported as detected.  
Information from collected samples 
Slovenia reported a sample of a brown powder which was purchased from an Internet vendor. The 
sample was apparently shipped from China and was received in August 2016. The precursor  4-
ANPP was also detected in the sample. 
Information from biological samples 
Serious adverse events (deaths and acute intoxications) with confirmed exposure to 
tetrahydrofuranylfentanyl from biological samples are discussed in Section D. 
Availability, supply, price 
The available data suggests that tetrahydrofuranylfentanyl is sold online as a powder and as ready-to-
use nasal sprays. 
Information on production 
No information was reported in relation to the production of tetrahydrofuranylfentanyl. 
Information on trafficking 
No information was reported to the EMCDDA in relation to the trafficking of tetrahydrofuranylfentanyl. 
Information on the source of tetrahydrofuranylfentanyl is limited to one report regarding a test 
purchase of the substance. Here, the substance was ordered from an online vendor apparently based 
in China (see above). 
Availability from Internet vendors 
Tetrahydrofuranylfentanyl is sold on the surface web. Its availability on the darknet is not currently 
known. As mentioned above, a collected sample of the substance was ordered from an online vendor 
apparently based in China which supplied 5 grams. 
 17 
In addition, two sites apparently based in Sweden offered tetrahydrofuranylfentanyl in liquid form as 
nasal sprays at claimed concentrations of 10 mg/ml and 13 mg/ml. The price of a 10 ml nasal spray 
(both concentrations) was EUR 51. The price for 25 ml was EUR 118 (for the 13 mg/ml solution). 
Prevalence of use  
No studies were identified that have investigated the prevalence of use of tetrahydrofuranylfentanyl in 
the general population. Given its pharmacology and that it is sold openly as a  replacement to 
illicit opioids, it would be expected that users looking for substitutes for opioids, which would include 
individuals who use illicit opioids, such as heroin and/or prescription opioids, may seek out 
tetrahydrofuranylfentanyl and other fentanils. It also appears that there is interest in this substance by 
some psychonauts. Overall, the available information does not suggest widespread use of the 
substance. 
Of additional note is that, in the past few years, fentanils have been sold in Europe as ready-to-use 
nasal sprays. In some cases they have also been sold as e-liquids for vaping. In general, these novel 
products could make it easier to use such substances (with similar effects to injecting) and make them 
more socially acceptable, potentially expanding their use in new user groups. These are new 
developments that will require careful monitoring. Nasal sprays claiming to contain 
tetrahydrofuranylfentanyl have been offered by online vendors within the European Union. 
Section D. Health risks 
D1. Acute health effects 
D1.1. Animal data 
Data on the acute toxicity, abuse liability, and dependence producing potential of 
tetrahydrofuranylfentanyl could not be identified.  
D1.2. Human data 
No clinical studies were identified that have examined the acute health effects of 
tetrahydrofuranylfentanyl and/or its metabolites in humans. Although the pharmacology and toxicology 
of tetrahydrofuranylfentanyl remains largely unstudied, the available data suggests that the nature of 
its effects share some similarities with opioid analgesics such as morphine and fentanyl. The acute 
effects of these types of opioids include: euphoria, relaxation, analgesia, sedation, bradycardia, 
hypothermia, miosis, and respiratory depression or arrest. They also have an abuse liability and 
dependence potential (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; Romberg et al., 2003). 
Similar to other opioid analgesics, the most serious acute health risk associated with 
tetrahydrofuranylfentanyl use is probably respiratory depression, which can lead to apnoea, 
respiratory arrest and death (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; White & Irvine, 1999). 
This risk may be greater due to: the difficulty in diluting the substance; a lack of experience with its 
effects and dosing; the use of other central nervous system depressants at the same time (such as 
other opioids, benzodiazepines, gabapentanoids, and alcohol); a lack of tolerance to opioids; and, 
using the substance alone (such as at home) which would make it more difficult for users to call for 
help in the case of poisoning. 
The antidote naloxone should reverse acute poisoning caused by tetrahydrofuranylfentanyl (Kim and 
Nelson, 2015). 
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Recent clinical and community experience in treating poisonings caused by fentanils suggests that 
larger than normal doses and repeated doses of naloxone may be required to manage the poisoning 
in some cases; longer periods of observation may also be required (Klar et al., 2016; Moss et al., 
2017; Somerville et al., 2017; Sutter et al., 2017). 
Data from serious adverse events associated with tetrahydrofuranylfentanyl are discussed below. 
Information from a single case of acute intoxication with confirmed exposure to 
tetrahydrofuranylfentanyl, suggests that the clinical features of poisoning may be similar to those 
found with fentanyl and other opioid analgesics. These include reduced level of consciousness or 
unconsciousness, respiratory depression and arrest, and miosis. 
Acute intoxications reported by the Member States 
A single case of acute intoxication with confirmed exposure to tetrahydrofuranylfentanyl was reported 
to the EMCDDA (26). The case occurred in Sweden in October 2016, and involved a 26 year old male 
who had administered 8 actuations of a 'fentanyl' nasal spray. The poisoning was classed as severe. 
The clinical features were consistent with the use of an opioid analgesic, and included reduced 
consciousness, respiratory depression and miosis. The patient was treated with 0.2 mg of naloxone 
(route of administration and response was not reported). The only other substance detected was 
flunitrazolam. The patient survived. This case has also been published in the literature (Helander et 
al., 2017). 
Acute intoxications identified from other sources 
Acute intoxications identified from other sources are limited to the case presented above (Helander et 
al., 2017). 
Deaths reported by the Member States 
A total of 14 deaths were reported by 1 Member State: Sweden. In all cases, exposure to 
tetrahydrofuranylfentanyl was analytically confirmed from post-mortem samples (femoral blood or 
muscle).  
The deaths occurred between September 2016 and March 2017 with 8 occurring in 2016 and 6 in 
2017. 
Of these deaths, 8 were male (57%) and 6 were female (43%). The mean age of the males was 31 
years (median 29) and ranged from 25 to 41 years; the mean age of the females was 32 years 
(median 30) and ranged from 29 to 38 years. 
Circumstances and cause of death 
In all but one case, the individuals were found dead (predominantly in a home environment). In all 
cases there was a lack of information regarding symptoms experienced by the deceased prior to 
death. Consequently, it was not possible to identify or evaluate ante-mortem symptoms (especially in 
relation to acute intoxication). 
                                                     
(26) In addition, Sweden also reported 2 acute intoxications with suspected exposure to tetrahydrofuranylfentanyl. These cases 
are not discussed further in this report. 
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The cause of death was reported in 13 out of 14 cases. In at least 12 deaths, intoxication with 
tetrahydrofuranylfentanyl was reported either as the primary cause of death or as likely to have 
contributed to death (even in presence of other substances); other substances were detected in all 14 
cases. 
Tetrahydrofuranylfentanyl was quantified in 5 cases. Post-mortem femoral blood concentrations 
ranged from 2 to 54 ng/g blood (median 18 ng/g blood). Due to the toxicity of opioids and variability in 
user tolerance, determination of a fatal  concentration based on a post-mortem blood concentration 
may not be reliable. In the majority of circumstances involving fentanils, the mere presence of the 
drug is of significance whether concentration has been determined or not, especially in situations of 
poly-drug use. 
A range of other substances were detected in the reported deaths, including: benzodiazepines, 
zopiclone, pregabalin, antidepressants, antipsychotics, antihistamines, synthetic cathinones, 
anticonvulsants and ethanol. Other opioids were detected in 3 of the deaths; tramadol, 
benzodioxolfentanyl and acryloylfentanyl. 
Overall, whilst other substances may have contributed some toxicity, a synergistic effect with 
tetrahydrofuranylfentanyl would have been likely with other central nervous system depressants such 
as ethanol, benzodiazepines, opioids, etc. Nevertheless, the apparent fentanyl-like nature of 
tetrahydrofuranylfentanyl means that the primary toxic contribution could be attributed to the 
tetrahydrofuranylfentanyl and death may not have occurred if tetrahydrofuranylfentanyl had not been 
used. An assessment of the Toxicological Significance Score (TSS) (Elliott, Sedefov, & Evans-Brown, 
2017) incorporating the above considerations showed that tetrahydrofuranylfentanyl had a TSS value 
of 3 (high) in 13 out of 14 of the deaths (where it was cited as the cause of death or is likely to have 
contributed to death). In the remaining death, an alternative pathological cause of death was cited 
(TSS value of 1, low). 
Deaths identified from other sources 
Since December 2016, at least 2 deaths associated with tetrahydrofuranylfentanyl have been 
reported in the United States. No further details are available on these cases (US DEA, 2017a). 
D2. Chronic health effects 
D2.1. Animal data 
No studies were identified that have investigated the chronic health effects of 
tetrahydrofuranylfentanyl in animals. 
D2.2. Human data 
No studies were identified that have investigated the chronic health effects of 
tetrahydrofuranylfentanyl in humans. 
D3. Factors affecting public health risks 
D3.1. Availability and quantity of the new psychoactive substance on the market 
Tetrahydrofuranylfentanyl is being sold on the surface web as a drug in its own right. It has been sold 
as a   in several physical forms, such as powders and ready-to-use nasal sprays. 
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D3.2. Availability of the information, degree of knowledge and perceptions amongst users 
concerning the psychoactive substance and its effects 
Due to its relatively recent availability on the drug market, the availability of information, degree of 
knowledge and perceptions amongst users concerning tetrahydrofuranylfentanyl and its effects are 
limited. 
D3.3. Characteristics and behaviour of users  
No studies were identified that have examined the characteristics and behaviours of users of 
tetrahydrofuranylfentanyl. Section C (above) and Section E6 (below) provides additional information 
on the likely user groups of tetrahydrofuranylfentanyl. 
D3.4. Nature and extent of health consequences 
Acute health risks 
Although the pharmacology and toxicology of tetrahydrofuranylfentanyl remains largely unstudied, the 
available data suggests that the nature of its effects share some similarities with opioid analgesics 
such as morphine and fentanyl.  
The acute effects of these types of opioids include: euphoria, relaxation, analgesia, sedation, 
bradycardia, hypothermia, and respiratory depression. They also have an abuse liability and 
dependence potential (Cox, 2011; Dahan et al., 2001; Pattinson, 2008). 
Similar to other opioid analgesics, the most serious acute risk arising from the use of 
tetrahydrofuranylfentanyl is probably from respiratory depression, which can lead to apnoea, 
respiratory arrest, and death (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; White & Irvine, 1999).  
In general, this risk may be exacerbated by:  
 the difficulty in diluting/using fentanils (as they are typically highly potent), which can lead to a 
toxic dose being accidentally used (de Boer et al., 2003; Sutter et al., 2017); 
 the apparent rapid onset of severe poisoning following use (Somerville et al., 2017); 
 using routes of administration that allow large amounts of the substance to rapidly reach the 
central nervous system (such as injecting, insufflation, and inhalation) (Macleod et al., 2012);  
 availability of easy to use dosage forms (such as nasal sprays and e-liquids); 
 lack of awareness and experience of users with these new substances (effects and dosage); 
 use of other central nervous system depressants (such as other opioids, benzodiazepines, 
and alcohol) (e.g. van der Schrier et al., 2017) ;  
 lack of tolerance to opioids in opioid-naïve persons (such as new or former users); 
 use in environments where it may be difficult to summon help in the event of poisoning (e.g. 
alone in a home environment) (Somerville et al., 2017); 
 limited availability of the antidote naloxone in community settings (EMCDDA, 2015; 
EMCDDA, 2016; Somerville et al., 2017). 
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In addition, and, often unknown to users, the fentanils are sold as heroin or mixed with heroin. They 
are also used to make counterfeits of highly sought-after analgesics and benzodiazepines. They have 
also been sold in or as drugs such as cocaine (Klar et al., 2016; SFDPH, 2015; Sutter et al., 2017; 
Tomassoni et al., 2017). Due to this, users may not be aware that they are using a fentanil; in some 
cases these individuals will have no tolerance to opioids nor access to community naloxone 
programmes. Overall, these factors may increase the risk of life-threatening poisoning. 
Given the above risks, poisonings by fentanils may manifest as outbreaks which have the potential to 
overwhelm emergency responders and other local healthcare systems (Klar et al., 2016; SFDPH, 
2015; Sutter et al., 2017; Tomassoni et al., 2017). 
Accidental exposure to the fentanils may also pose a risk to non-users, including family and friends, 
law enforcement and emergency responders. Such risks may need to be assessed so that, where 
required, appropriate procedures, training and environmental and personal protective measures can 
be provided for handling materials suspected to contain these substances (IAB, 2017; US CDC, 2016; 
Moss et al., 2017; US DEA, 2017a). Any required responses should continue to ensure the delivery of 
prompt and appropriate care to patients with suspected overdose (Cole & Nelson, 2017; Lynch, 
Suyama, & Guyette, 2017). 
Managing poisoning 
The antidote naloxone should reverse acute poisoning caused by tetrahydrofuranylfentanyl (Kim and 
Nelson, 2015; Ujváry et al., 2017). Recent clinical and community experience in treating poisonings 
caused by fentanils suggests that larger than normal doses and repeated doses of naloxone may be 
required to manage the  poisoning in some cases, longer periods of observation may also be required 
(Klar et al., 2016; Moss et al., 2017; Somerville et al., 2017; Sutter et al., 2017). This may reflect, 
among other factors, the high potency of the fentanils, their half-lives, the dose an individual is 
exposed to, and, the relatively short half-life of naloxone. 
Chronic health risks 
While there is limited data, the chronic health risks of tetrahydrofuranylfentanyl might share some 
similarities to opioids such as heroin and other fentanils. This may include dependence. 
D3.5. Long-term consequences of use 
While there is limited data, the chronic health risks of tetrahydrofuranylfentanyl might share some 
similarities to opioids such as heroin and other fentanils. This may include dependence. 
D3.6. Conditions under which the new psychoactive substance is obtained and used, 
including context-related effects and risks 
There is limited data on the conditions which tetrahydrofuranylfentanyl is obtained and used. 
Tetrahydrofuranylfentanyl is offered for sale on the surface web, typically as powders and ready-to-
use nasal sprays.  
Section E. Social Risks 
While there have been no studies on the social risks of tetrahydrofuranylfentanyl, it is likely that some 
of the risks are similar to those associated with illicit opioids, including fentanyl and heroin. 
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E1. Individual social risks 
There is no information on the individual social risks that may be associated with the use of 
tetrahydrofuranylfentanyl. Given that tetrahydrofuranylfentanyl appears to act as an opioid analgesic, 
any such risks may have some similarities with those associated with illicit opioids. These may 
negatively impact on education or career, family or other personal and social relationships and may 
result in marginalisation. 
E2. Possible effects on direct social environment  
There is no information on the possible effects of tetrahydrofuranylfentanyl on the direct social 
environment. Given that tetrahydrofuranylfentanyl appears to act as an opioid analgesic, any such 
effects may have some similarities with those associated with the use of illicit opioids. 
E3. Possible effects on society as a whole 
There is no specific information on the possible effects of tetrahydrofuranylfentanyl on society as a 
whole.  
As discussed above, accidental exposure to the fentanils may pose a risk of poisoning to those who 
may come into contact with the substances. This includes the family and friends of users, law 
enforcement, emergency personnel, medical and forensic laboratory personnel as well as custodial 
settings and postal services. Where required, these risks should be assessed and appropriate 
procedures, training, and protective measures should be implemented. This may include training in 
managing poisoning, including in resuscitation and adequate provision of naloxone to reverse 
poisoning. Any required responses should continue to ensure the delivery of prompt and appropriate 
care to patients with suspected overdose (Cole & Nelson, 2017; Lynch, Suyama, & Guyette, 2017). 
E4. Economic costs 
There are no data on the health and social costs related to tetrahydrofuranylfentanyl. 
E5. Possible effects related to the cultural context, for example marginalisation 
There are no data on the possible effects of tetrahydrofuranylfentanyl related to the cultural context. 
E6. Possible appeal of the new psychoactive substance to specific population groups within 
the general population 
While no specific examples are available on the possible appeal of tetrahydrofuranylfentanyl to 
specific user groups (aside from psychonauts), it is reasonable to assume tetrahydrofuranylfentanyl 
may be sought by those looking for  substitutes for illicit opioids, such as heroin and/or 
prescription opioids.  
As discussed above, the open sale of solutions of fentanils in novel dosage forms such as ready-to-
use nasal sprays and e-liquids for vaping poses additional concerns. These novel forms have the 
potential to make the use of fentanils easier (with similar effects to injecting) and more socially 
acceptable.  
Section F. Involvement of organised crime 
F1. Evidence that criminal groups are systematically involved in production, trafficking and 
distribution for financial gain 
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There is no specific information to suggest the involvement of organised crime or established criminal 
groups in the manufacture, distribution and supply of tetrahydrofuranylfentanyl. 
Slovenia reported a collected sample of tetrahydrofuranylfentanyl to Europol and the EMCDDA where 
the country of origin was reported as China (27). 
The seizure of an illicit laboratory producing fentanils in Europe in 2013 (EMCDDA, 2017b) suggests 
that the capability to manufacture fentanils may exist within the European Union. 
F2. Impact on the production, trafficking and distribution of other substances, including 
existing psychoactive substances as well as new psychoactive substances 
No information was reported nor identified concerning the impact of tetrahydrofuranylfentanyl on the 
production, trafficking and distribution of other substances, including existing psychoactive 
substances as well as new psychoactive substances. 
F3. Evidence of the same groups of people being involved in different types of crime 
No information was reported nor identified concerning evidence of the same groups of people being 
involved in different types of crime related to the availability of tetrahydrofuranylfentanyl. 
F4. Impact of violence from criminal groups on society as a whole or on social groups or local 
communities (public order and safety) 
No information was reported nor identified concerning incidents of violence related to the availability 
of tetrahydrofuranylfentanyl. 
F5. Evidence of money laundering practices, or impact of organised crime on other 
socioeconomic factors in society 
No information was reported nor identified concerning evidence of money laundering practices, or 
impact of organised crime on other socioeconomic factors in society related to the availability of 
tetrahydrofuranylfentanyl. 
F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial 
system)  
No information was reported nor identified concerning the economic costs and consequences related 
to the availability of tetrahydrofuranylfentanyl. 
F7. Use of violence between or within criminal groups 
No information was reported nor identified concerning the use of violence between or within criminal 
groups related to the availability of tetrahydrofuranylfentanyl. 
                                                     
(27) The sample also contained 4-aminophenyl-1-phenethylpiperidine (4-ANPP), a precursor that can be used for the synthesis 
of fentanyl and many fentanil analogues. 
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F8. Evidence of strategies to prevent prosecution, for example through corruption or 
intimidation 
No information was reported nor identified concerning evidence of strategies to prevent prosecution 
related to the availability of tetrahydrofuranylfentanyl. 
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